WHO:s instruction for Crimean–Congo hemorrhagic fever is given in this link:

http://www.who.int/mediacentre/factsheets/fs208/en/

Based on this I should isolate the neonate till you are sure she/he is not infected. The incubation period following contact with infected blood or tissues is usually five to six days, with a documented maximum of 13 days. If the child is not infected perhaps a relative can care for her/him for the time needed. The mother has a 70% chance to survive. This is just a lay woman's opinion, medical doctors can give you more informed advise.  

Here is a paper about the transplacental transmission in case of CCHF::

A healthy newborn born to a mother with Crimean-Congo hemorrhagic fever: is there protection from transplacental transmission? 

Aydemir O, Erdeve O, Oguz SS, Dilmen U

Source

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 14:5 2010 May pg e450

Dear Beatrice;

Many thanks.

Is Ribavirin safe for neonate if she/he is positive for CCHF (PCR).Should we treated baby in this time? and do you prescribe ribavirin prophylaxis in baby if it is not infected?

Best

Batool

Dear Batool

Here is a paper where they used ribavirin for neonate:

The Journal of Pediatrics

Volume 130, Issue 4, April 1997, Pages 612–615

Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: Pharmacokinetics and clearance by hemofiltration

Christoph Aebi, MD,

Catherine L. Headrick, RN, MS,

George H. McCracken Jr., MD,

Christine A. Lindsay, Pharm D

Abstract

Intravenously administered ribavirin (20 mg/kg per day) was given to a neonate with disseminated adenovirus infection requiring extracorporeal membrane oxygenation and hemofiltration. Plasma concentrations at steady state were 4.81 to 8.47 μg/ml, hemofiltration sieving coefficient was 0.85, and hemofiltration clearance (0.046 L/kg per hour) was similar to the renal clearance reported with normal kidney function. Despite low plasma concentrations, results of viral cultures were negative within 48 hours of initiation of ribavirin therapy, suggesting that plasma concentrations may not adequately predict inhibition of adenovirus replication in vivo. (J Pediatr 1997;130:612-5)

I would though ask some of my doctor friends Ankush and Kamal to comment on this.

Further:

Respir Care. 1986 Dec;31(12):1188-96.

Administration of ribavirin to neonatal and pediatric patients during mechanical ventilation.

Demers RR, Parker J, Frankel LR, Smith DW.

Abstract

We have modified the circuits of pressure-preset and volume-preset ventilators to permit the administration of ribavirin to mechanically ventilated infants suffering from respiratory syncytial virus. The modifications isolate the ventilator itself and permit continuous aerosolization for as long as seven days without ventilator malfunction from the effects of crystallized medication. Excessive spilling of ribavirin into the environment is also avoided. Each institution must devise its own experimental protocols and gain permission from its own committee on human experimentation and from the parent/guardian of the patient before administering such treatment.

J Pediatr. 2014 Mar;164(3):529-35.e1-4. doi: 10.1016/j.jpeds.2013.11.009. Epub 2013 Dec 18.

Neonatal adenoviral infection: a seventeen year experience and review of the literature. Ronchi A, Doern C, Brock E, Pugni L, Sánchez PJ

OBJECTIVES:

To describe the clinical manifestations and short-term outcomes of adenoviral infections in neonates and review all published cases to better determine impact and treatment outcomes.

STUDY DESIGN:

Retrospective cohort study of all neonates hospitalized at Children's Medical Center (CMC) and Parkland Memorial Hospital (PMH), Dallas, TX with laboratory-confirmed adenoviral infection from January 1,1995-December 31, 2012. Neonates were identified by review of the CMC Virology Laboratory's prospective database of all positive adenovirus tests performed in the inpatient and ambulatory settings, and at PMH, of a prospective neonatal database that included all neonatal intensive care unit admissions. Patients also were identified by discharge International Classification of Disease, 9th edition codes for adenoviral infection. The medical records were reviewed, and a review of the English literature was performed.

RESULTS:

During 17 years, 26 neonates had adenoviral infection (25, CMC; 1, PMH). The principle reasons for hospitalization were respiratory signs (88%) and temperature instability (65%). Five (19%) had disseminated disease and 4 (80%) of these infants died. Ribavirin or cidofovir treatment, as well as immune globulin intravenous, did not improve outcomes except in 1 neonate. Literature review (n = 72) combined with our data found that disseminated infection was associated with death (68% vs 21% with localized infection, P < .001). In addition, neonates

Dear Beatrice;

Many many  thanks for your comments.

Dear Batool

Dr Ankush Sachdeva recommends this link:

emedicine.medscape.com/article/2042311-overview and

recommends Zidovidine.pls 

Clin Pharmacol. 2001 Jul;41(7):732-41.

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.

Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, Mudd PN Jr, Pakes GE.

Abstract

A phase I, repeat-dose, open-label study was conducted to determine the pharmacokinetics and safety of zidovudine and lamivudine, coadministered orally every 12 hours, in 16 neonates whose mothers were infected with human immunodeficiency virus type 1 (HIV-1). The prospective mothers had been stabilized on a zidovudine/lamivudine regimen since week 36 of pregnancy to prevent mother-to-child transmission of HIV. During 1 week postpartum, the mothers received zidovudine 300 mg plus lamivudine 150 mg every 12 hours and breastfed. Neonatal treatment was initiated 12 hours following birth with 4 mg/kg of zidovudine suspension plus 2 mg/kg of lamivudine solution every 12 hours; this regimen was continued for 1 week. Between days 1 and 7 of neonatal treatment, the neonatal oral clearance (CL/F) of zidovudine and lamivudine increased by 2-fold (p < 0.001) and 1.6-fold (p = 0.004), respectively, possibly reflecting maturation of intestinal hepatic and renal function occurring during the first week of life. Day 7/day 1 ratios for exposure (area under the serum concentration-time curve [AUC]) and maximum observed serum concentration (Cmax) were 0.48 and 0.63, respectively, for zidovudine and 0.64 and 0.73, respectively, for lamivudine. At the time of delivery, the geometric mean cord/maternal concentration ratio was 1.24 for zidovudine and 1.12 for lamivudine, indicating free passage of each drug across the placenta. The maternal and neonatal treatment regimens were well tolerated. The results of this study confirm that in the neonate, a convenient regimen combining zidovudine 4 mg/kg and lamivudine 2 mg/kg, administered orally every 12 hours, provides zidovudine serum exposure very similar to that reported with the standard neonatal zidovudine regimen of 2 mg/kg every 6 hours, as well as lamivudine serum exposure within the range reported in adults receiving lamivudine 150 mg twice a day and children receiving 4 mg/kg twice a day.

Dear Beatrice;

My patient had CCHF no HIV and I am searching about Pregnancy / CCHF and outcome in neotate.

Thanks

Yes I understood that. Now I see that  Ribavirin is the only known treatment for a variety of viral hemorrhagic fevers, including Lassa fever, Crimean-Congo hemorrhagic fever, Venezuelan hemorrhagic fever, and Hantavirus infection, although data regarding these infections are scarce and the drug might be effective only in early stages-. I see also that Ribavirin should not be given with zidovudine because of the increased risk of anemia. Sorry, I trusted the advise I got. Hope all is well with the baby?